



Draft Resolutions of the Ordinary General Meeting of Shareholders

The Ordinary General Meeting of Shareholders of Antibiotice S.A. Iasi, a trading company established and operating according to the Romanian law, registered at the Trade Register Office Iasi attached to the Court of Iasi, under the no. J22/285/1991, unique registration code RO1973096, headquartered in 1 Valea Lupului St., Iasi, Romania, having subscribed and paid-up capital in the amount of 67,133,804 LEI divided in 671,338,040 ordinary registered shares, with a nominal value of 0.10 lei each,

convened by the announcement published in the Official Gazette of Romania, Part IV, no./09.08.2024 and in Evenimentul no. dated on 09.08.2024,

according to the provisions of Law no. 31/1990 on trading companies, republished, with the subsequent amendments and completions, Law no. 24/2017 on issuers of financial instruments and market operations, republished, Financial Supervisory Authority (FSA) Regulation no. 5/2018 on issuers of financial instruments and market operations, with the subsequent amendments and completions, Government Emergency Ordinance no. 109/2011 on corporate governance of public enterprises and provisions of the company's Articles of Association,

reunited on 12.09.2024 at 10 AM for an Ordinary Meeting at Antibiotice headquarters, for the first reunion, gathering shareholders that represent% of the share capital, respectively% of the total no. of voting rights, statutory and legally constituted,

following the debates,

DECIDES:

<u>**Resolution no.1:**</u> With the "for"/"against" votes of the shareholders representing% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not approve the H1 2024 Management Report according to art. 55 of GEO no. 109/2011 on the corporate governance of public enterprises.

<u>**Resolution no.2</u>**: With the "for"/"against" votes of the shareholders representing% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not approve the H1 2024 Statutory Auditor's Report according to art. 55 of GEO no. 109/2011 on the corporate governance of public enterprises.</u>

<u>**Resolution no.3:**</u> With the "for"/"against" votes of the shareholders representing% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not

approve the H1 2024 Financial Statements of Antibiotice S.A. according to art. 55 of GEO no. 109/2011 on the corporate governance of public enterprises.

<u>**Resolution no.4</u>**: With the "for"/"against" votes of the shareholders representing% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not approve the integral component of the Selection Plan within the selection procedure of the administrators of Antibiotice S.A. initiated by the Decision no. 4 taken within the OGMS of 14.09.2023.</u>

<u>**Resolution no.5**</u>: With the "for"/"against" votes of the shareholders representing% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not approve a 2-month extension (16.09.2024 - 16.11.2024) of the interim mandates for the company administrators and the signing of additional documents to the mandate contracts.

This decision shall be signed today 12.09.2024 at the company's headquarters, in two original copies.

President of the Management Board, *Ionut-Sebastian IAVOR*